High-Dose Palliative Radiotherapy with Chemotherapy for Lung Cancer
Author Information
Author(s): Michael M, Wirth A, Ball D L, MacManus M, Rischin D, Milner A D, Solomon B, McKendrick J
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
Can the addition of concurrent chemotherapy improve outcomes in patients with non-small-cell lung cancer unsuitable for radical therapy?
Conclusion
The study found that the combination of high-dose palliative radiotherapy with weekly chemotherapy was tolerable and produced meaningful responses in patients with locally advanced lung cancer.
Supporting Evidence
- 65% of patients showed a radiological response after treatment.
- Grade 4 neutropenia was the most common dose-limiting toxicity observed.
- Patients reported improvements in symptoms and quality of life.
- Overall survival was estimated at 13.5 months.
- 92% of patients had stage IIIB or limited stage IV disease.
Takeaway
Doctors tested a new treatment for lung cancer that combines radiation and chemotherapy to help patients feel better, and it worked well for many of them.
Methodology
Patients received high-dose palliative radiotherapy along with weekly doses of Vinorelbine and Cisplatin, with dose escalation to determine tolerability and response.
Potential Biases
Potential selection bias due to the rigorous eligibility criteria and the use of FDG-PET for staging.
Limitations
The study was limited by its small sample size and the phase I trial design, which may not fully capture the efficacy of the treatment.
Participant Demographics
The majority of participants were male, over 60 years old, with stage IIIB or limited stage IV disease.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI: 34–77%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website